Caz Investments LP Sells 7,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Caz Investments LP lowered its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 75.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,500 shares of the company’s stock after selling 7,500 shares during the quarter. ARS Pharmaceuticals makes up approximately 0.0% of Caz Investments LP’s holdings, making the stock its 27th biggest holding. Caz Investments LP’s holdings in ARS Pharmaceuticals were worth $36,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SPRY. Vanguard Group Inc. boosted its position in shares of ARS Pharmaceuticals by 37.0% in the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after purchasing an additional 779,969 shares during the last quarter. SG Americas Securities LLC lifted its stake in ARS Pharmaceuticals by 861.5% in the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock valued at $950,000 after buying an additional 99,986 shares during the period. Allspring Global Investments Holdings LLC bought a new position in ARS Pharmaceuticals during the third quarter worth about $2,584,000. Royce & Associates LP grew its position in shares of ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock worth $10,026,000 after buying an additional 45,755 shares during the period. Finally, First Turn Management LLC bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at about $8,603,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Price Performance

Shares of SPRY stock opened at $14.37 on Wednesday. ARS Pharmaceuticals, Inc. has a 12-month low of $4.65 and a 12-month high of $18.51. The firm has a fifty day moving average of $14.79 and a 200-day moving average of $11.93.

Analyst Ratings Changes

SPRY has been the topic of several recent analyst reports. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals has an average rating of “Buy” and an average target price of $24.00.

Insider Buying and Selling

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the sale, the insider now directly owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. The trade was a 9.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total transaction of $1,293,000.00. Following the transaction, the chief executive officer now owns 1,398,499 shares of the company’s stock, valued at approximately $18,082,592.07. This represents a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 850,956 shares of company stock valued at $14,037,346. Company insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.